Organisation paid for research Program year 2024 Source: CMS Open Payments

Fellows Research Alliance

Neither a doctor nor a teaching hospital

Research payments

$1,105,368

197 payments

Through program year 2024, Fellows Research Alliance is reported as receiving $1,105,368 in research payments, across 197 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$13,558	1
2023	Research	$182,644	26
2022	Research	$684,738	18
2021	Research	$38,064	12
2020	Research	$28,048	9
2019	Research	$158,315	131

Breakdown

Who paid Research payments · program years 2019–2024

Becton, Dickinson and Company $615,600 16 payments
Bayer HealthCare Pharmaceuticals Inc. $170,763 134 payments
Exeltis, USA Inc. $141,141 19 payments
Novartis Pharmaceuticals Corporation $79,369 4 payments
Mylan Technologies Inc. $52,857 6 payments
AstraZeneca Pharmaceuticals LP $10,648 1 payment
Sumitomo Pharma America, Inc. $10,355 3 payments
Mylan Inc. $10,347 4 payments
AbbVie, Inc. $8,242 6 payments
Myovant Sciences Inc. $6,046 4 payments

Studies the money was for Research payments · program years 2019–2024

Maxmm1 $340,979 3 payments
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women $131,532 16 payments
BAY1002670 Long term Safety vs SoC $124,675 89 payments
Covid BioSpec $111,176 4 payments
Sust030 $89,380 2 payments
Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $79,369 4 payments
Sust031 $52,994 2 payments
Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $52,857 6 payments
Bay1002670 Fibroids Efficacy US / CN $46,088 45 payments
Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes $10,648 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.